TR199801418T2 - Rekombinant a�� vekt�rleri kar���m�. - Google Patents

Rekombinant a�� vekt�rleri kar���m�.

Info

Publication number
TR199801418T2
TR199801418T2 TR1998/01418T TR9801418T TR199801418T2 TR 199801418 T2 TR199801418 T2 TR 199801418T2 TR 1998/01418 T TR1998/01418 T TR 1998/01418T TR 9801418 T TR9801418 T TR 9801418T TR 199801418 T2 TR199801418 T2 TR 199801418T2
Authority
TR
Turkey
Prior art keywords
weightlifting
kar
recombinant
treatment
viruses
Prior art date
Application number
TR1998/01418T
Other languages
English (en)
Turkish (tr)
Inventor
Hurwitz Julia
Coleclough Christopher
Owens Randall
Slobod Karen
Original Assignee
St.Jude Children's Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St.Jude Children's Research Hospital filed Critical St.Jude Children's Research Hospital
Publication of TR199801418T2 publication Critical patent/TR199801418T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TR1998/01418T 1996-01-23 1997-01-23 Rekombinant a�� vekt�rleri kar���m�. TR199801418T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/590,288 US5741492A (en) 1996-01-23 1996-01-23 Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Publications (1)

Publication Number Publication Date
TR199801418T2 true TR199801418T2 (xx) 1998-10-21

Family

ID=24361647

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01418T TR199801418T2 (xx) 1996-01-23 1997-01-23 Rekombinant a�� vekt�rleri kar���m�.

Country Status (28)

Country Link
US (3) US5741492A (OSRAM)
EP (2) EP0876498B1 (OSRAM)
JP (2) JP2000504326A (OSRAM)
KR (1) KR100571479B1 (OSRAM)
CN (1) CN1229501C (OSRAM)
AP (1) AP1200A (OSRAM)
AT (1) ATE278790T1 (OSRAM)
AU (1) AU709174B2 (OSRAM)
BG (1) BG64711B1 (OSRAM)
BR (1) BR9707611A (OSRAM)
CA (1) CA2243570C (OSRAM)
CZ (1) CZ296575B6 (OSRAM)
DE (1) DE69731075T2 (OSRAM)
DK (1) DK0876498T3 (OSRAM)
EA (1) EA002390B1 (OSRAM)
ES (1) ES2230596T3 (OSRAM)
GE (1) GEP20032902B (OSRAM)
HU (2) HU0402182D0 (OSRAM)
IL (2) IL125497A (OSRAM)
NO (1) NO322261B1 (OSRAM)
NZ (1) NZ331024A (OSRAM)
OA (1) OA10814A (OSRAM)
PL (1) PL188641B1 (OSRAM)
PT (1) PT876498E (OSRAM)
RO (1) RO120268B1 (OSRAM)
TR (1) TR199801418T2 (OSRAM)
UA (1) UA73712C2 (OSRAM)
WO (1) WO1997027311A1 (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488485B2 (en) * 2003-09-16 2009-02-10 University Of Kansas Medical Center DNA vaccine compositions and methods of use
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6919318B1 (en) * 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
WO1999061049A2 (en) * 1998-05-22 1999-12-02 University Of Massachusetts Medical Center Model for infection by a pathogen using administration of nucleic acids
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
CA2348382C (en) * 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
JP4776075B2 (ja) * 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
JP2002533124A (ja) * 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
US20030194800A1 (en) * 2001-08-31 2003-10-16 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1144014B1 (en) * 1999-01-28 2005-07-27 Stichting Biomedical Primate Research Center Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors
DE19907485B4 (de) * 1999-02-12 2008-01-17 Strathmann Ag & Co. Virus-Vakzine
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
WO2001037878A2 (en) * 1999-11-29 2001-05-31 Orchid Biosciences, Inc. Methods of identifying optimal drug combinations and compositions thereof
AU2002211948B2 (en) 2000-03-02 2007-09-13 Emory University DNA expression vectors and methods of use
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
CA2417240A1 (en) * 2000-08-07 2002-02-14 Sloan-Kettering Institute For Cancer Research Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
WO2002080982A2 (en) * 2001-01-12 2002-10-17 Chiron Corporation Nucleic acid mucosal immunization
PT1372710E (pt) * 2001-03-08 2009-12-21 Us Gov Health & Human Serv Vam modificado que expressa os genes gag e pol do envelope de vih
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030198621A1 (en) * 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20070269456A1 (en) * 2001-11-05 2007-11-22 Lasher Alfred W DNA-based plasmid formulations and vaccines and prophylactics containing the same
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
WO2003047617A2 (en) 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US20040106566A1 (en) * 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
DE60335755D1 (de) * 2002-07-18 2011-02-24 Univ Washington Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
WO2004050856A2 (en) * 2002-12-03 2004-06-17 University Of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
AU2004238367A1 (en) * 2003-05-12 2004-11-25 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
CA2537953A1 (en) * 2003-09-09 2005-03-17 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to hiv in humans
CN1913919B (zh) 2003-09-15 2011-10-19 美国政府健康及人类服务部 基于hiv多进化枝的env的hiv疫苗
EP1667631A4 (en) * 2003-09-15 2010-04-14 Novartis Vaccines & Diagnostic COMBINATION PATHS FOR GENERATING IMMUNE RESPONSES
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
WO2005117964A2 (en) 2004-05-27 2005-12-15 Centocor, Inc. Cynomolgus prostate specific antigen
US20050276758A1 (en) * 2004-06-15 2005-12-15 Marshall Deborah J Method for screening agents against human prostate disease
ATE527281T1 (de) * 2004-07-16 2011-10-15 Us Gov Health & Human Serv Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
US20080085261A1 (en) * 2004-10-19 2008-04-10 Haynes Barton F Vaccine Adjuvant
EP1814583A2 (en) * 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
NZ555830A (en) * 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
WO2008048984A2 (en) * 2006-10-18 2008-04-24 St. Jude Children's Research Hospital Methods and compositions for preparing a universal influenza vaccine
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2012070974A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Вакцины с повышенной иммуногенностью и способы их получения
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
AP2013007166A0 (en) 2011-04-06 2013-10-31 Univ Paris Descartes Inst De Rech Pour Le Dev Ird Pharmaceutical compositions for preventing and/or treating an HIV disease in humans
US9393300B2 (en) 2011-11-14 2016-07-19 Novartis Ag Immunogenic complexes of polyanionic carbomers and Env polypeptides and methods of manufacture and use thereof
WO2013126622A1 (en) 2012-02-24 2013-08-29 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
EP3390430B1 (en) * 2015-12-15 2019-08-28 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
IT202100000569A1 (it) * 2021-01-14 2022-07-14 Evobiotech S R L Composizione comprendente vescicole extracellulari vegetali ingegnerizzate e suo impiego come vaccino

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198214A (en) * 1983-08-31 1993-03-30 Stolle Research & Development Corporation Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
EP0243029A1 (en) * 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Recombinant vaccinia virus expressing human retrovirus gene
US5169763A (en) * 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
US5081226A (en) * 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
DE69031735T2 (de) * 1989-04-18 1998-03-12 Applied Biotechnology Inc Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
WO1992022641A1 (en) * 1991-06-14 1992-12-23 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP0740704A1 (en) * 1994-01-27 1996-11-06 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro

Also Published As

Publication number Publication date
IL156919A0 (en) 2004-02-08
KR19990081931A (ko) 1999-11-15
CN1214083A (zh) 1999-04-14
NZ331024A (en) 2000-02-28
DE69731075D1 (de) 2004-11-11
AP1200A (en) 2003-08-29
HK1016218A1 (en) 1999-10-29
AU1829997A (en) 1997-08-20
DK0876498T3 (da) 2005-02-07
EA002390B1 (ru) 2002-04-25
US5846546A (en) 1998-12-08
JP2000504326A (ja) 2000-04-11
HUP9900389A2 (hu) 1999-06-28
EP0876498B1 (en) 2004-10-06
JP2007259870A (ja) 2007-10-11
EA199800638A1 (ru) 1999-02-25
PL328193A1 (en) 1999-01-18
AU709174B2 (en) 1999-08-26
DE69731075T2 (de) 2006-03-09
NO983377D0 (no) 1998-07-22
HU224344B1 (hu) 2005-08-29
CN1229501C (zh) 2005-11-30
IL125497A0 (en) 1999-03-12
US6086891A (en) 2000-07-11
RO120268B1 (ro) 2005-11-30
OA10814A (en) 2003-01-28
GEP20032902B (en) 2003-02-25
PT876498E (pt) 2005-02-28
EP1378516A1 (en) 2004-01-07
CA2243570A1 (en) 1997-07-31
HU0402182D0 (en) 2004-12-28
US5741492A (en) 1998-04-21
NO322261B1 (no) 2006-09-04
HUP9900389A3 (en) 2001-06-28
BG64711B1 (bg) 2005-12-30
BG102712A (en) 1999-04-30
KR100571479B1 (ko) 2007-06-07
PL188641B1 (pl) 2005-03-31
NO983377L (no) 1998-09-23
WO1997027311A1 (en) 1997-07-31
EP0876498A1 (en) 1998-11-11
AP9801325A0 (en) 1998-09-30
ATE278790T1 (de) 2004-10-15
CZ296575B6 (cs) 2006-04-12
CA2243570C (en) 2001-08-14
UA73712C2 (en) 2005-09-15
ES2230596T3 (es) 2005-05-01
IL125497A (en) 2007-07-04
CZ229398A3 (cs) 1998-12-16
BR9707611A (pt) 1999-07-27

Similar Documents

Publication Publication Date Title
TR199801418T2 (xx) Rekombinant a�� vekt�rleri kar���m�.
ATE315667T1 (de) Amplifizierung und detektion von hiv-1 und/oder hiv-2
CY1107393T1 (el) Τροποποιημενα env πολυπεπτιδια του hiv
FR2731013B1 (fr) Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
DE60023300D1 (de) Verwendung von cpg als adjuvans für hivimpstoff
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ATE59845T1 (de) Pflanzenschuetzende mittel auf basis von 1,2,4triazolderivaten sowie neue derivate des 1,2,4triazols.
HUP0002224A1 (hu) Virusellenes hatású benzimidazol-származékok
FI953717L (fi) 4-Hydroksibentsopyran-2-oneja ja 4-hydroksisykloalkyyli(b)pyran-2-oneja, joita voidaan käyttää retrovirusinfektioiden hoitamiseen
EE9700201A (et) Aminohappe hüdroksüetüülamino-sulfoonamiidsed retroviirusliku proteaasi inhibiitorid
PT1052250E (pt) Inibidores de protease retroviral sulfonilalcanoilamino hidroxietilamino sulfonamidas
TR200002921T2 (tr) Yarı-Sentetik ekteinasidinler
PT1169057E (pt) Vacina anti-hiv-1 compreendendo o todo ou parte de uma proteina tat de vih-1
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
TR199802704T2 (xx) H�V tedavisinde Vx478, Zidov�din, FTC ve/veya 3TC i�eren kombinasyonlar�n kullan�m�.
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
EP1036165A4 (en) HUMAN RNASE-H AND COMPOSITIONS AND USES THEREOF
TR200001745T2 (tr) Keton peroksit türevleri, bunların hazırlanması ve kullanılması
ATE308306T1 (de) Verwendung von wasserunlöslichen linearen poly- alpha-glucan als uv-filter
ATE189460T1 (de) Gegen protozoen wirksamezyklische tetrapeptide
BG101175A (bg) Тройна анти-нiv комбинация
TR199802703T2 (xx) HIV tedavisinde Vx478, Zidov�din, ve/veya 1592U89 i�eren kombinasyonlar�n kullan�m�.
BR9611904A (pt) Dioxidos de ditiazol
DK0393530T3 (da) 5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-oner og -thioner og deres anvendelse til forebyggelse eller behandling af AIDS